The latest update is out from Y-Mabs Therapeutics ( (YMAB) ).

Y-mAbs Therapeutics announced a strategic business realignment to enhance operational flexibility and accelerate clinical development. The company will establish two business units focusing on radiopharmaceuticals and DANYELZA. This realignment includes a workforce reduction of up to 13% and relocation of roles from Denmark to the U.S. to optimize resources. The restructuring is expected to incur expenses of up to $2.6 million, impacting financial results through early 2026. Despite these changes, Y-mAbs plans to continue advancing its SADA PRIT platform and DANYELZA's commercial potential, with significant milestones anticipated in 2025.

More about Y-Mabs Therapeutics

Y-mAbs Therapeutics is a commercial-stage biopharmaceutical company that develops and commercializes novel radioimmunotherapy and antibody-based therapeutic cancer products. The company is focused on two key areas: the development of its Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and the commercialization of DANYELZA, an FDA-approved treatment for relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.